Registered report: Systematic identification of genomic markers of drug sensitivity in cancer cells

Registered report: Systematic identification of genomic markers of drug sensitivity in cancer cells

The Reproducibility Project: Cancer Biology seeks to address growing concerns about the reproducibility in scientific research by conducting replications of selected experiments from a number of high-profile papers in the field of cancer biology. The papers, which were published between 2010 and 201...

Full description

Bibliographic Details
Main Authors:	John P Vanden Heuvel, Jessica Bullenkamp, Reproducibility Project: Cancer Biology
Format:	Article
Language:	English
Published:	eLife Sciences Publications Ltd 2016-06-01
Series:	eLife
Subjects:	Reproducibility Project: Cancer Biology methodology Ewing's sarcoma poly(ADP-ribose) polymerase PARP mesenchymal progenitor cells
Online Access:	https://elifesciences.org/articles/13620

Similar Items

Replication Study: Systematic identification of genomic markers of drug sensitivity in cancer cells
by: John P Vanden Heuvel, et al.
Published: (2018-01-01)

PARG suppresses tumorigenesis and downregulates genes controlling angiogenesis, inflammatory response, and immune cell recruitment
by: Sarah Johnson, et al.
Published: (2022-05-01)

ADP-Ribosylation as Post-Translational Modification of Proteins: Use of Inhibitors in Cancer Control
by: Palmiro Poltronieri, et al.
Published: (2021-10-01)

Disrupting Poly(ADP-ribosyl)ating Pathway Creates Premalignant Conditions in Mammalian Liver
by: Yaroslava Karpova, et al.
Published: (2023-12-01)

Poly(ADP-Ribose) Glycohydrolase (PARG) vs. Poly(ADP-Ribose) Polymerase (PARP) – Function in Genome Maintenance and Relevance of Inhibitors for Anti-cancer Therapy
by: Daniel Harrision, et al.
Published: (2020-08-01)

Fused in Sarcoma (FUS) in DNA Repair: Tango with Poly(ADP-ribose) Polymerase 1 and Compartmentalisation of Damaged DNA
by: Maria V. Sukhanova, et al.
Published: (2020-09-01)

Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report
by: Andrew D. Simmons, et al.
Published: (2020-03-01)

Discovery of 2-(1-(3-(4-Chloroxyphenyl)-3-oxo- propyl)pyrrolidine-3-yl)-1<i>H</i>-benzo[d]imidazole-4-carboxamide: A Potent Poly(ADP-ribose) Polymerase (PARP) Inhibitor for Treatment of Cancer
by: Rui Min, et al.
Published: (2019-05-01)

Hematological Toxicities with PARP Inhibitors in Prostate Cancer: A Systematic Review and Meta-Analysis of Phase II/III Randomized Controlled Trials
by: Gartrell C. Bowling, et al.
Published: (2023-10-01)

Mechanism of PARP inhibitor resistance and potential overcoming strategies
by: Xiaoyu Fu, et al.
Published: (2024-01-01)

Nanoparticle Formulations of Poly (ADP-ribose) Polymerase Inhibitors for Cancer Therapy
by: Bijay Singh, et al.
Published: (2020-11-01)

A Double-Edged Sword: The Two Faces of PARylation
by: Mincheol Kang, et al.
Published: (2022-08-01)

Inhibition of Poly ADP-Ribose Glycohydrolase Sensitizes Ovarian Cancer Cells to Poly ADP-Ribose Polymerase Inhibitors and Platinum Agents
by: Emad Matanes, et al.
Published: (2021-10-01)

A Novel PARP Inhibitor YHP-836 For the Treatment of BRCA-Deficiency Cancers
by: Tingting Du, et al.
Published: (2022-07-01)

A Review on DNA Repair Inhibition by PARP Inhibitors in Cancer Therapy
by: Shah Ashish P., et al.
Published: (2018-03-01)

Structural implications for selective targeting of PARPs
by: Jamin D. Steffen, et al.
Published: (2013-12-01)

Reduced Tumorigenicity of Mouse ES Cells and the Augmented Anti-Tumor Therapeutic Effects under <i>Parg</i> Deficiency
by: Yuki Sonoda, et al.
Published: (2020-04-01)

Automodified Poly(ADP-Ribose) Polymerase Analysisto Monitor DNA Damagein Peripheral Lymphocytes of Floriculturists Occupationally Exposed to Pesticides
by: Serena Imperato, et al.
Published: (2019-02-01)

Development and characterization of new tools for detecting poly(ADP-ribose) in vitro and in vivo
by: Sridevi Challa, et al.
Published: (2022-04-01)

PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do?
by: Amelia Barcellini, et al.
Published: (2021-10-01)

Human PARP1 Facilitates Transcription through a Nucleosome and Histone Displacement by Pol II In Vitro
by: Elena Y. Kotova, et al.
Published: (2022-06-01)

DNA damage repair protein PARP1 poly (ADP-ribosyl) ates mitotic protein BUB3 regulates mitosis in HeLa cells
by: YANG Xue, et al.
Published: (2023-08-01)

Towards Personalized Management of Ovarian Cancer
by: Algethami M, et al.
Published: (2022-12-01)

Targeting PARP1 to Enhance Anticancer Checkpoint Immunotherapy Response: Rationale and Clinical Implications
by: Carlos Wagner S. Wanderley, et al.
Published: (2022-04-01)

PARP Inhibitors: An Innovative Approach to the Treatment of Inflammation and Metabolic Disorders in Sepsis
by: Wasyluk W, et al.
Published: (2021-05-01)

PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting
by: Karolina N. Dziadkowiec, et al.
Published: (2017-02-01)

Inhibiting poly(ADP-ribosylation) improves axon regeneration
by: Alexandra B Byrne, et al.
Published: (2016-10-01)

Reduced Colonic Mucosal Injury in 2,3,7,8-Tetrachlorodibenzo-<i>p</i>-Dioxin Poly ADP-Ribose Polymerase (TIPARP/PARP7)-Deficient Mice
by: David Hutin, et al.
Published: (2022-01-01)

Molecular Insights into Poly(ADP-ribose) Recognition and Processing
by: Ivan Ahel, et al.
Published: (2012-12-01)

In Vivo Level of Poly(ADP-ribose)
by: Masanao Miwa, et al.
Published: (2018-05-01)

Editorial: Inhibiting PARP as a Strategic Target in Cancer
by: Kristin eZorn, et al.
Published: (2016-04-01)

PARP14 is increased in the hippocampus of three mouse depression models and its relationship with neuroinflammation
by: LI Chen, XIU Jian-bo, XU Qi
Published: (2021-05-01)

PARP Traps Rescue the Pro-Inflammatory Response of Human Macrophages in the In Vitro Model of LPS-Induced Tolerance
by: Julita Pietrzak, et al.
Published: (2021-02-01)

The Role of PARP1 in Monocyte and Macrophage Commitment and Specification: Future Perspectives and Limitations for the Treatment of Monocyte and Macrophage Relevant Diseases with PARP Inhibitors
by: Maciej Sobczak, et al.
Published: (2020-09-01)

A New Opportunity for “Old” Molecules: Targeting PARP1 Activity through a Non-Enzymatic Mechanism
by: Pablo Iglesias, et al.
Published: (2023-05-01)

Active Targeted Nanoparticles for Delivery of Poly(ADP-ribose) Polymerase (PARP) Inhibitors: A Preliminary Review
by: Saman Sargazi, et al.
Published: (2021-09-01)

Interactions of PARP1 Inhibitors with PARP1-Nucleosome Complexes
by: Natalya Maluchenko, et al.
Published: (2022-10-01)

What Plasma Can Tell Us When Tissue Cannot: A Case Report of Genomic Testing in mCRPC and Clinical Response to Treatment With the PARP Inhibitor Rucaparib
by: Daniel P. Petrylak, et al.
Published: (2022-08-01)

PARP7 and Mono-ADP-Ribosylation Negatively Regulate Estrogen Receptor α Signaling in Human Breast Cancer Cells
by: Marit Rasmussen, et al.
Published: (2021-03-01)

Registered report: Intestinal inflammation targets cancer-inducing activity of the microbiota
by: Kate Eaton, et al.
Published: (2015-03-01)